TCXB

10.2901.06%
CY

Chen-Ming Yu

Chief Executive Officer

Dr. Chen-Ming Yu, also known as Chen, M.D., M.B.A., is Chief Executive Officer of TCGX Acquisition Corp. II since June 16, 2026 and had been its Director since June 16, 2026 until October 15, 2026. He serves as a Board Director at Corxel Pharmaceuticals Limited and Corxel Pharmaceuticals, Inc. He was Independent Director of ADARx Pharmaceuticals, Inc. from August 09, 2023 to September 24, 2026. Dr. Yu is Chief Executive Officer at TCGX Acquisition Corp. since May 26, 2026. He served as Independent Director of LB Pharmaceuticals Inc since December 2023 until September 10, 2025. He was a Director of TCGX Acquisition Corp. since May 26, 2026 until August 4, 2026. He is the Founder and Managing Partner at TCG Crossover Management, LLC. Dr. Yu is the Founder and Managing Partner at TCGX, which was founded in January 2021. He served as a Director of Upstream Bio, Inc. from October 2021 to July 2024. Prior to joining TCG X, Dr. Yu was a Managing Partner at Vivo Ventures. Dr. Yu has extensive operating experience with leadership roles at both private and public companies. Dr. Yu also serves on the California Board of Trustees for the ElevAATe Biotechnology since November 2024. Dr. Yu has served on the boards of several life science companies in both the US and China, including Artios Pharma, ShouTi, Tarsus, Kala, Surgical Specialties (acquired by GTCR), Rempex (acquired by MDCO) and Sentre Heart (acquired by Atricure). Dr. Yu served as the Managing Partner at Vivo Capital, LLC. Dr. Yu joined Vivo Capital, LLC in 2004. At Vivo, he invested in both private and public pharmaceutical and medical device companies in the US and China. He served as Other Professional of Microsoft Advertising. Dr. Yu served as an Interim Chief Operating Officer at Sagent Pharmaceuticals, Inc. since 2012 until March 7, 2013. He served as the Chief Business Officer at China KangHui Holdings since 2010 until to 2012. He was responsible for overseeing their corporate development and investor relations efforts since 2010. He was an Executive at aQuantive, Inc. Dr. Yu has extensive operating experience with leadership roles at both private and public companies like aQuantive (AQNT). Notably, Dr. Yu has played a leading industry role in facilitating cross border deals between emerging market and US healthcare companies. Prior to his time at Vivo, Dr. Yu was an early employee at a Quantive as a Group Product Manager and led the team that designed, developed and launched its first suite of ad targeting software. He served as a board of directors at Artios Pharma Limited until August 2025. He serves as Director at SentreHEART, Inc. and of ShouTi, Inc. since October 20, 2021. He serves as a Member of the Board of Directors of Outpost Medicine, LLC. He serves as a Director at KangHong Pharmaceuticals, Sagent Holding Co., Synaptic International, Nora Therapeutics, Inc., Trauson, Cubist, Achillion, GMT Medical, Jian Rui Bao, Ocera and PAVAD Medical, Inc. He served as a Member of Supervisory Board at Nabriva Therapeutics AG since April 2, 2015 until August 25, 2016. He served on the Board of Naryx Pharma, Inc. He served as a Director of Rempex Pharmaceuticals, Inc. He served as a Director of Kala Pharmaceuticals, Inc. since April 2016. He served as a Director of Sagent Pharmaceuticals, Inc. from May 2006 to May 23, 2012. Dr. Yu is the owner of multiple patents for his innovations in technology and the life sciences. His research background was focused on immunology and infectious diseases and he has also published several research articles and several peer review articles in the fields of infectious disease and immunology in journals such as the Journal of Experimental Medicine. Dr. Yu also serves on the California Board of Trustees for the Nature Conservancy and was previously a member of the Stanford Medical School Alumni Board of Governors. He served as a Director of Arbor Biotechnologies, Inc. since November 09, 2021 until October 2025. He holds an M.D. and an M.B.A. from the Stanford University and a B.A. in Biology, magna cum laude, from Harvard University.

Positions